title: The synthesis of 191Pt labelled JM216, an orally active platinum anti-tumour agent.
abstract: The orally active platinum anti-tumour complex JM216[bis-acetatoamminedichlorocyclohexylamineplatinum(IV)] is at present in stage II clinical trials. A procedure for synthesising the complex labelled with 191Pt or 188Pt at the platinum centre has been developed. The purity (shown by HPLC) is 98% and the specific activity (0.3-0.4 Ci/kg) is enough for in vivo and in vitro studies.
authors.affiliation: Department of Medical Biophysics, University of Manchester, Medical School, UK.
authors.forename: P I
authors.initials: PI
authors.lastname: Bates
authors.forename: H L
authors.initials: HL
authors.lastname: Sharma
authors.forename: B A
authors.initials: BA
authors.lastname: Murrer
authors.forename: C F
authors.initials: CF
authors.lastname: Bernard
authors.forename: C A
authors.initials: CA
authors.lastname: McAuliffe
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000138:chemical synthesis*; D007553:Isotope Labeling / Q000379:methods; D009944:Organoplatinum Compounds / Q000138:chemical synthesis*; D010984:Platinum / Q000737:chemistry*; D011786:Quality Control; D011868:Radioisotopes / Q000737:chemistry*
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D011868:Radioisotopes; D010984:Platinum; C081294:satraplatin